Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis vaccines and diagnostics ltd - neisseria meningitidis group c capsular polysaccharide protein conjugate - powder and solvent for suspension for injection

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

nuron biotech b.v. - neisseria meningitidis group c capsular polysaccharide protein conjugate - suspension for injection

Belçika - İngilizce - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - conjugate of haemophilus influenzae type b capsular polysaccharide and tetanus toxoid 12,5 ; neisseria meningitidis group c polysaccharides conjugated to tetanus toxoid as a carrier 5 - powder and solvent for solution for injection - haemophilus influenzae type b polysaccharides, conjugated to tetanus toxoid; neisseria meningitidis c, polysaccharides conjugated to tetanus toxoid as a carrier - hemophilus influenzae b, combinations with pertussis and toxoids

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - neisseria meningitidis c tetanus toxoid - suspension for injection

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - conjugate of haemophilus influenzae type b capsular polysaccharide (polyribosylribitol phosphate) and tetanus; conjugate of neisseria meningitides c capsular polysaccharide and tetanus toxoid (mean tt/ps ratio :1) - powder and solvent for solution for injection - 0.5 millilitre(s) - hemophilus influenzae b, combinations with meningococcus c, conjugated

Malta - İngilizce - Medicines Authority

nuron boitech b.v. - corynebacterium diphtheriae crm197 carrier protein; neisseria meningitidis polysaccharide group c; aluminium - suspension for injection - corynebacterium diphtheriae crm197 carrier protein 15 µg; neisseria meningitidis polysaccharide group c 10 µg; aluminium - vaccines

Malta - İngilizce - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - aluminium, corynebacterium diphtheriae, crm, carrier protein, neisseria meningitidis, polysaccharide group - suspension for injection in pre-filled syringe - aluminium corynebacterium diphtheriae crm197 carrier protein 15 µg neisseria meningitidis polysaccharide group c 10 µg - vaccines

ABD - İngilizce - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen (unii: t4gyx3110d) (neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen - unii:t4gyx3110d), neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen (unii: zt89e5a103) (neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen - unii:zt89e5a103), neisseria meningitidis group w-135 capsular polysaccharide tetanus toxoid conj - penbraya is indicated for active immunization to prevent invasive disease caused by neisseria meningitidis serogroups a, b, c, w, and y. penbraya is approved for use in individuals 10 through 25 years of age. do not administer penbraya to individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of penbraya [see description (11)] .              pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to penbraya during pregnancy. individuals who received penbraya during pregnancy are encouraged to contact, or have their healthcare provider contact, 1-877-390-2953 to enroll in or obtain information about the registry. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. there are no clinical studi

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - meningococcal polysaccharide - group w135; meningococcal polysaccharide - group a; meningococcal polysaccharide - group y; meningococcal polysaccharide - group c -

Malta - İngilizce - Medicines Authority

pfizer healthcare ireland - neisseria meningitidis polysaccharide group c 10 µg, aluminium 10 µg, corynebacterium diphtheriae crm197 carrier protein 10 µg - suspension for injection